April 7, 2021, Singapore – Evive Biotech, a global biologics company developing novel biological therapies, has obtained a Manufacture License of Pharmaceutical Products (MLPP) from the Beijing Municipal Medical Products Administration for the production of biopharmaceutical products in Evive Beijing’s GMP manufacturing facility. The permit was granted after the facility successfully passed an on-site inspection.

“We are very pleased to have received the MLPP for Evive’s Beijing GMP facility,” said Dr. Jubo Liu, Evive Biotech’s CEO. “It is yet another step that brings us closer to delivering strong first-line treatments to patients worldwide who are contraindicated or refractory to current treatment options. This includes F-627, our novel biological treatment for chemotherapy-induced neutropenia, which we plan to manufacture at our GMP facility following regulatory approval.”